160929 umc presentarion molecule to business
30
SMB, Nijmegen 29 september 2016 Radboudumc als businesspartner
-
Upload
smbbv -
Category
Health & Medicine
-
view
160 -
download
0
Transcript of 160929 umc presentarion molecule to business
SMB, Nijmegen
29 september 2016
Radboudumc als businesspartner
Dirkjan MasmanFrom public to private to technology transfer2013 Valorization Radboudumc 2011 Radboud Translational Research BV (Cyclotron on Radboud Campus)2007 Business Generator Groningen (RUG & UMC Groningen)2005 Angteq BV (UMC Groningen)2003 Aesculaap BV (Utrecht University)1996 Leadd BV (Leiden University)1991 Institute for Veterinarian Research BV (Wageningen University)1988 Groningen University, Postdoc1986 University of Washington, Seattle, USA, Research fellow1982 Groningen University, PhD
To take home• Medisch onderzoek is gericht op “unmet medical needs”
• Innovaties komen bij patiënt via commercialisatie
• Publiek-Private Consortia zijn onontbeerlijk
• Radboudumc is “dus” ook een zakenpartner
Radboud Campus Nijmegen
Radboud Campus Nijmegen
Total employees: 5.050Academic staff: 2.914Annual turnover: € 542 millionStudents: 18.891Scientific publications: 6.716PhD Theses: 384
Total employees: 11.000Annual turnover: € 1 billionBeds: 1000Medical specialists: 587Students: 3.300Professors: 147Scientific publications: 3.396PhD theses: 186
Patient
Radboud Personalized Healthcare
A significant impact
on healthcare
Molecule
Population
5
Research themes and institutes
6www.radboudumc.nl/Research/Themes/Pages/default.aspx
NWO 10 juni 2016: Spinozapremie voor onderzoek naar afweersysteem
Valorisation Department (20 fte)• Business Development
Spin-offs, licenses, patents
• Legal AffairsMTA, NDA, CTA
• Subsidies & FinanceHorizon2020, ERC, NWO, EFRO
• (Project) Support
• Direct report to Board of Directors• Strong support Holding Company
ProfessionalsPublicationsShareholderLicenseContract ResearchJoint Research
Impact of Radboudumc
TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Inve
ster
ings
risi
co
Imp
act
on
hea
lth
care
Radboudumc beleid ‘van idee tot spin-off’
TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Inve
ster
ings
risi
co
Imp
act
on
hea
lth
care
CHECK door
Octrooifonds
• Onderzoek financiering
• 1e, 2e & 3e geldstroom
Radboud Innovatie Fonds
SUPPORT door
Subsidies, non-diluting cash
Radboudumc beleid ‘van idee tot spin-off’
TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Inve
ster
ings
risi
co
Imp
act
on
hea
lth
care
CHECK door
Seed
Late stage VC’s
& banks
Thuja Capital & PPM oost
Octrooifonds
• Onderzoek financiering
• 1e, 2e & 3e geldstroom
Radboud Innovatie Fonds
SUPPORT door
Subsidies, non-diluting cash
Radboudumc Holding B.V.
Pre-Seed
Radboudumc beleid ‘van idee tot spin-off’
TRL1 TRL2 TRL3 TRL4 TRL5 TRL6 TRL7 TRL8 TRL9
IMPACT
Inve
ster
ings
risi
co
Imp
act
on
hea
lth
care
CHECK door
Seed
Late stage VC’s
& banks
Thuja Capital & PPM oost
Octrooifonds
• Onderzoek financiering
• 1e, 2e & 3e geldstroom
Radboud Innovatie Fonds
SUPPORT door
Subsidies, non-diluting cash
Radboudumc Holding B.V.
Pre-Seed
Radboudumc beleid ‘van idee tot spin-off’
LS&H portfolio Radboud Holding BV
Year Spin-off’s founded
1996 1
2006 1
2007 1
2008 1
2009 1
2011 2
2012 3
2013 1
2014 4
2015 4
• Holding founded in 2007• 19 companies (founded and aquired)• 153 fte• € 44 million invested
Founded 11-11-2014
Product: MedValue helps medical technology companies to extend their market opportunities, reduce the(financial) risks and to improve their impact and profit. MedValue provides options (report) to optimize the added value of innovations for patients and other stakeholders.
Via Medvalue 4 “state of the art” Radboudumc operation rooms will be prepared, fully equipped with intra-operative imaging (CT, MRI, Echography), in vivo microscopy, intra-operative radiotherapy en intra-operative navigation. These facilities are also accessible for companies for testing, trials en training sessions.
CEO: Richard van den BroekHeadcount: 7www.medvalue.nl
CEO: Juliëtte van den DolderHeadcount: 1
Stem cell researchers need 3D scaffolds to mimic human nature.Batch variation, animal origin, cell recovery are drawbacks of current 3D scaffolds.
Noviocell´s technology is poly isocyanopeptide (PIC) hydrogel.
PIC hydrogel is:• reproducible • synthetic• ease of cell recovery • performs uniquely like collagen• allows for modularity and
tailoring of scaffold properties
Noviocell develops a 3D solution for stem cell researchers
3D human organs2D cell culture ware
Tubular structures of Huvec cells
in PIC hydrogel with RGD peptide, VEGF and FGF
PIC hydrogel performs uniquely like collagen
Founded 12-11-2015
Binnenkort
Meniscus prothese Multimodal imaging New Statines
To take home• Medisch onderzoek is gericht op “unmet medical needs”
• Innovaties komen bij patiënt via commercialisatie
• Publiek-Private Consortia zijn onontbeerlijk
• Radboudumc is “dus” ook een zakenpartner
Dirkjan Masman (PhD) Director Knowledge and Technology Transfer OfficeRadboud University Medical Center
Reinier Postlaan 2, HP9036525 GC NijmegenThe Netherlands
[email protected] +31(0)24 3651500Mob.+31 (0)6 222 473 56
Founded in 2006Exit September 2015, still on Campus
Product: a molecular diagnostic research and service company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnostic assays for the uro-oncological practice.
MDx HealthCEO: J. Groen, PhDCOO: Chr. ThibodeauAdvisors Dr. Willem Melchers and Prof. Dr. Jack Schalken, RUMC
Legal entity founded: March 2007Operational start: November 2012
Products: Pre-clinical and clinical drug candidates for mitochondrial diseasewww.khondrion.com
CEO: Prof. dr. Jan SmeitinkHeadcount: 12
www.khondrion.com
Founded 18-8-2011
Product: RTM b.v. has been established with the objective of creating a fully equipped cyclotron facility. In this facility we aim to manufacture a range of GMP compliant, routine and experimentalradiopharmaceuticals for our internal customers (research institutes of the Radboudumc) as well as for external clients.
CEO: Frans Pieters Headcount: 10www.radboudtranslationalmedicine.nl
Founded 2-8-2012
Activity: discovery and development of drugs against malaria.
CEO: dr. Koen DecheringHeadcount: 8www.tropIQ.nl
Founded 8-10-2012
Product: Development, production and sales of medical devices and instruments - specifically in the field of Magnetic Resonance Imaging (MRI) and MR-guided interventions.
CEO: Jan SabischCTO: Gerrit TigelaarHeadcount: 3www.soteria-medical.com
Founded 9-10-2013
Product: life-prolonging therapeutics for advanced prostate cancer. A central process for an incipient cancer cell to become invasive is epithelial-to-mesenchymal transition (EMT). Oncodrone’s proprietary drug candidate (OCD155) reverses the EMT, thereby destroying the cancer.
CEO: Henk ViëtorCSO: Jack SchalkenHeadcount: 4www.oncodrone.com
Founded 28-2-2014
Product:Development of computer algorithms for analyzing medical imaging data. Thirona current focus is on quantitative computed tomography analysis for obstructive lung diseases. www.thirona.com
CEO: Eva van RikxoortCSO: Bram van GinnekenHeadcount: 13www.thirona.eu
Founded 8-5-2014
Product:ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis. Initially, ScreenPoint will develop and market a next generation system for computer aided detection in screening mammography.
CEO: Nico Karssemeijer, Michael BradyHeadcount: 2www.screenpoint-medical.com
